Roche   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Basel Switzerland (1896)

Organization Overview

First Clinical Trial
1992
NCT01060501
First Marketed Drug
1941
kappadione
First NDA Approval
1941
kappadione
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CHD de Vendee LA ROCHE SUR YON France | CHD La Roche sur Yon | CHD of La Roche/Yon | CHD Vendee | CHD VENDEE - La Roche sur Yon | F. Hoffmann-La Roche | F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute | HLR | Hofffmann-La Roche | HOFFMAN-LA ROCHE | Hoffmann-LaRoche | Hoffmann-La Roche | HOFFMANN LA ROCHE | HOFFMANN-LA ROCHE | Hoffmann-La Roche, 973-235-5000 | nv Roche sa | ROCHE | Roche, Austria | Roche BV Netherlands | Roche Chugai | Roche, Copenhagen | Roche Diagnostics | Roche Diagnostics International AG | Roche Farma, S.A | Roche for trial and Saquinavir,and Abbott for Kaletra | Roche Foundation of Anemia Research (RoFAR, Switzerland) | Roche-Genentech | Roche/Genentech Inc. | Roche/Genetech | Roche Global Development | Roche (Grenzach-Wyhlen, Germany) | Roche Korea co.,Ltd. | Roche Molecular Systems, Inc | ROCHE PALO | Roche Pharma AG | Roche Pharma AG, 79639 Grenazch Wyhlen, Germany | Roche Pharma, Italy | Roche Products (India) Pvt. Ltd. | Roche Products Pty Limited | Roche - Prof. Dr. Jens Huober et al. | Roche S.p.a | Roche SpA | Roche Therapeutics Ltd